You are here

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Last updated on February 28, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Edmonton, Alberta, T6G 2B7 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must have participated and completed the previous Pegvisomant studies or have
shown to be unresponsive to other conventional therapies

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- ALT/AST>3 times the ULN or have hepatic disease

- have severe visual field loss, cranial nerve palsies or intracranial HTN that requires
surgery to decompress the tumor

- unwilling to self-administer the medication.

NCT00151437
Pfizer
Completed
Canadian Pegvisomant Compassionate Study In Acromegalic Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now